Movement Alert｜IDEXX Laboratories Falls 6.08% in Regular Trading, Target Price Cuts Emerge Ahead of Earnings

Market Focus10-31 03:09

On October 31, IDEXX Laboratories fell 6.08% in Regular Trading, trading at $543.32 per share, with turnover of $293 million.

The clearest recent catalyst is a series of analyst target price reductions ahead of the company’s November 2 pre-market earnings release, which has contributed to a more cautious near-term tone around the stock.

Most recently, UBS cut its target price to $627 from $670 while maintaining a Neutral rating. Earlier, Jefferies reduced its target to $705 from $795, JPMorgan lowered its target to $750 from $775, and Barclays had previously trimmed its target to $710 from $800. Even so, analyst consensus remained broadly constructive, with an average target price around $718.73 and an average rating of overweight.

Operationally, IDEXX Laboratories delivered solid prior-quarter results, with revenue of $1.217 billion, up 9.66% year over year, and adjusted EPS of $4.27, up 17.63% and above market expectations. The next earnings report is expected to draw focus on whether growth and full-year guidance can support valuation after the recent target resets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment